Jacobio Pharma announced the approval of novel KRAS G12C inhibitor, glecirasib, for a pivotal study in pancreatic cancer by the Centre for Drug Evaluation (CDE). This approval marks an important milestone as it represents the first global registrational clinical study for KRAS G12C in the treatment of pancreatic cancer. A pivotal clinical trial has been approved in China to assess the effectiveness and safety of Glecirasib as a standalone treatment for pancreatic cancer patients who have already undergone second-line treatment or higher specifically for individuals with a KRAS G12C mutation in pancreatic cancer. The study results obtained from this pivotal trial will likely be used to support the submission of a New Drug Application (NDA) for Glecirasib as a potential treatment for pancreatic cancer with KRAS G12C mutation. Glecirasib is a novel KRAS G12C inhibitor, which specifically targets the KRAS G12C mutation found in certain solid tumours. These clinical trials are being conducted in China, the United States, and Europe, and their purpose is to evaluate the safety, tolerability, and efficacy of glecirasib in different patient populations with advanced solid tumours carrying the KRAS G12C mutation.
Sick and tired of always wondering if you are being asked to pay the right price for your APIs? This empowers you with the answers you need to make the right decisions in the Global API market.
Chemxpert Database is one of the biggest and most comprehensive directories of pharma and chemicals, manufacturers, suppliers and information. Provided with current information on prices, demand and transactions, it gives you instant feedback on whether you are buying what is right and at the right time.
Start using market intelligence today and allow yourself to be in control in the API market.
Check it out today and make more informed sourcing decisions! Learn More!